ProRx LLC

Has ProRx LLC received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued ProRx LLC 2 warning letters naming semaglutide and tirzepatide, the latest dated Apr 7, 2026, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” openFDA also lists 14 drug recall reports for the firm naming semaglutide and tirzepatide.

FDA records in this index name ProRx LLC from Aug 22, 2024 to Apr 7, 2026. It is listed on FDA’s registered 503B outsourcing facility list: ProRx LLC, Exton, PA.

Names in FDA records
ProRx LLC; ProRx, LLC
Type named in FDA records
Compounding pharmacy, 503B outsourcing facility
FDA warning letters
2
Drug recall reports
14
Drugs named
Semaglutide, Tirzepatide
Latest record
Apr 7, 2026
503B location
Exton, PA
503B last inspection
Sep 19, 2025
Form 483 issued
Yes
Action on last inspection
Warning Letter Issued 4/7/2026

FDA warning letters

Later letters FDA listsLetter
Apr 7, 2026Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Mar 4, 2025Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

Record
Oct 15, 2025Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 841...Lack of Assurance of SterilityClass IIOngoingD-0115-2026
Oct 15, 2025Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84...Lack of Assurance of SterilityClass IIOngoingD-0116-2026
Oct 15, 2025Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413...Lack of Assurance of SterilityClass IIOngoingD-0118-2026
Oct 15, 2025Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84...Lack of Assurance of SterilityClass IIOngoingD-0117-2026
Oct 15, 2025Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139...Lack of Assurance of SterilityClass IIOngoingD-0114-2026
Oct 15, 2025Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413...Lack of Assurance of SterilityClass IIOngoingD-0119-2026
Oct 15, 2025Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139...Lack of Assurance of SterilityClass IIOngoingD-0120-2026
Aug 22, 2024Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01Lack of Assurance of SterilityClass IIOngoingD-0650-2024
Aug 22, 2024Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02Lack of Assurance of SterilityClass IIOngoingD-0654-2024
Aug 22, 2024SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01Lack of Assurance of SterilityClass IIOngoingD-0652-2024
Aug 22, 2024SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04Lack of Assurance of SterilityClass IIOngoingD-0653-2024
Aug 22, 2024Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01Lack of Assurance of SterilityClass IIOngoingD-0651-2024
Aug 22, 2024TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02Lack of Assurance of SterilityClass IIOngoingD-0656-2024
Aug 22, 2024TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01Lack of Assurance of SterilityClass IIOngoingD-0655-2024

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

ProRX LLC, Exton, PA (503B)

4 listed actions, including 2 Form 483s and 2 warning letters (2024 to 2026).

Document
Apr 7, 2026Warning letterWarning Letter Issued 04/07/2026fda.gov
Sep 19, 2025Form 483483 Issued 09/19/2025fda.gov
Mar 4, 2025Warning letterAmended Warning Letter Issued 03/04/2025FDA copy (archived)
Aug 2, 2024Form 483483 Issued 08/02/2024FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: ProRx LLC, Exton, PA.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.